Based on statistical data provided by the World Health Organization, cancer is widely acknowledged as the foremost contributor to global mortality and persists as a significant concern in the contemporary era. In recent times, immunotherapy has been demonstrated as an efficacious approach in diverse advanced solid tumors, especially in thoracic tumors, consequently emerging as a prominent area of focus in the investigation of antitumor pharmaceuticals. The utilization of immunotherapy directed towards programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) has emerged as a valid approach, resulting in substantial enhancements in both disease-free and overall survival rates among cancer patients. Moreover, applications of multi-omics analyses in thoracic tumors have made great progress. However, it also ushered in new challenges. Certain subtypes of thoracic cancer have been identified as immune-quiescent tumors, indicating that only a limited number of patients would derive benefits from immunotherapy while also experiencing a high incidence of severe adverse events. Besides, multi-omics analyses reveal patterns of drug resistance and relapse in the treatment of thoracic tumors, which help us identify the molecular mechanisms that lead to drug resistance and provide clues for overcoming it. Meanwhile, exploring the role of the tumor microenvironment (TME) in the development and metastasis of thoracic tumors can help us better understand the potential mechanisms of tumor spread and find approaches to intervene.
This study encompasses a comprehensive examination of all facets pertaining to immunotherapies that specifically target the tumor microenvironment in cases of thoracic cancer.
We cordially invite the submission of Original Research, Brief Research Reports, Reviews, and Mini-Reviews with a primary focus on, though not exclusively limited to, the subsequent subtopics:
- Molecular mechanisms govern intercellular communication within TME
- Signaling pathways associated with the immune response within TME
- Therapeutic strategies aimed at modulating intercellular interactions within TME
- Novel strategies to enhance immunotherapy efficacy
- The relationship between tumor heterogeneity, TME, and immunotherapy in thoracic cancer
- Strategies for predicting and addressing immunotherapy resistance in thoracic cancer
- The process of TME reprogramming following immunotherapy for thoracic cancer
- Similarities, differences, and therapeutic outcomes associated with thoracic cancer immunotherapy
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.
Based on statistical data provided by the World Health Organization, cancer is widely acknowledged as the foremost contributor to global mortality and persists as a significant concern in the contemporary era. In recent times, immunotherapy has been demonstrated as an efficacious approach in diverse advanced solid tumors, especially in thoracic tumors, consequently emerging as a prominent area of focus in the investigation of antitumor pharmaceuticals. The utilization of immunotherapy directed towards programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) has emerged as a valid approach, resulting in substantial enhancements in both disease-free and overall survival rates among cancer patients. Moreover, applications of multi-omics analyses in thoracic tumors have made great progress. However, it also ushered in new challenges. Certain subtypes of thoracic cancer have been identified as immune-quiescent tumors, indicating that only a limited number of patients would derive benefits from immunotherapy while also experiencing a high incidence of severe adverse events. Besides, multi-omics analyses reveal patterns of drug resistance and relapse in the treatment of thoracic tumors, which help us identify the molecular mechanisms that lead to drug resistance and provide clues for overcoming it. Meanwhile, exploring the role of the tumor microenvironment (TME) in the development and metastasis of thoracic tumors can help us better understand the potential mechanisms of tumor spread and find approaches to intervene.
This study encompasses a comprehensive examination of all facets pertaining to immunotherapies that specifically target the tumor microenvironment in cases of thoracic cancer.
We cordially invite the submission of Original Research, Brief Research Reports, Reviews, and Mini-Reviews with a primary focus on, though not exclusively limited to, the subsequent subtopics:
- Molecular mechanisms govern intercellular communication within TME
- Signaling pathways associated with the immune response within TME
- Therapeutic strategies aimed at modulating intercellular interactions within TME
- Novel strategies to enhance immunotherapy efficacy
- The relationship between tumor heterogeneity, TME, and immunotherapy in thoracic cancer
- Strategies for predicting and addressing immunotherapy resistance in thoracic cancer
- The process of TME reprogramming following immunotherapy for thoracic cancer
- Similarities, differences, and therapeutic outcomes associated with thoracic cancer immunotherapy
Please NOTE: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Research Topic.